Stay updated with breaking news from Ace2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recently a team of researchers from Saudi Arabia, the United Arab Emirates, and the United States assessed travel-related anxiety in healthcare workers (HCWs) considering the emergence of new variants caused by SARS-CoV-2 mutations.
A team of international scientists has recently developed a bispecific antibody that can bind two non-overlapping regions of the spike receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and completely prevent the viral-host interaction.
A team of international scientists has demonstrated that therapeutic inhibition of a transcriptional regulator BRD2, required for the endogenous expression of angiotensin-converting enzyme 2 (ACE2), can potentially suppress severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv* preprint server.
Promising nanobodies against COVID-19 produced by llamas Thought LeadersDr. David BrodyProfessor of NeurologyUniformed Services University In this interview, News-Medical speaks to Dr. David Brody about his latest research that involved discovering nanobodies produced by llamas that could help combat coronavirus. What provoked your research into the ongoing COVID-19 pandemic? We are neuroscientists, so it was a bit of a shift in direction! For several years TJ and I had been testing out how to use nanobodies to make brain imaging better. When the pandemic broke, we thought this is a once in ...
Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide.